國際關係大師沈旭暉訪問一向好睇，最近就去咗台灣同蕭若元做訪問。一向沉默的沈旭暉，竟然在訪問中被蕭若元引到笑出來，甚為少見，很多網民都忍不住留言話第一次見沈旭暉笑。另外，蕭若元亦似乎燈力全開。沈旭暉問道蕭若元有生之年會否回香港，蕭若元提到好難，因為他覺得習總長命過佢。之後沈旭暉問道，香港有無廣義光復的希望，蕭若元說可見的情況沒有。
今次訪問只是上集，相信很多人期待下半集的訪問吧？
SINGAPORE - Staff at Changi Airport who come into close contact with passengers - such as swab assistants - will have to don full personal protective equipment (PPE) at work and be tested for Covid-19 every two weeks.
About 2,500 airport workers have already been tested for Covid-19 so far since last week, all with negative results. Another 1,000 or so more workers will be tested in the coming days, Transport Minister Ong Ye Kung told The Straits Times on Thursday (Oct 29).
The move comes after two workers at Terminal 3 were reported infected with Covid-19 last Saturday. One is a T3 security officer who had gone to work before being admitted to hospital.
The other is a screener and swab assistant at Raffles Medical at T3 who had gone to work before hospital admission.
The two had not interacted with each other, and investigations had not established any link between them, MOH said last week.
"As travel volume is expected to pick up in the coming months, MOH has been in discussion with relevant agencies to ramp up rostered routine testing of frontline staff working at Changi Airport," it added then.
Mr Ong said that both these workers had "come into close contact with passengers". Contact tracing is underway to identify those deemed to be close contacts.
While both had worn face masks, and gloves, Mr Ong said: "I think that's not enough, so we are going to tighten up the process."
He said staff at the airport will be put on a rostered routine testing similar to other frontline workers and migrant workers.
"For workers that come into close contact with passengers, they should don full PPE.
"Changi Airport Group will also step up the frequency of cleaning and disinfection."
Full PPE includes equipment such as gloves, gowns, caps and goggles.
More details about the safety precautions are expected to be released in the coming days.
The authorities have tested several groups of workers in recent months as part of efforts to prevent the spread of Covid-19.
For example, around 11,000 people working in public bus depots and interchanges were screened for Covid-19 following the discovery of an infection cluster at Bukit Panjang's transport centre. These include all bus drivers as well as employees such as administrative staff.
Mr Ong said the Government takes the situation at Changi Airport very seriously, and will draw on its experience to address it.
"When we were dealing with the spreading of the virus in the dormitories and in Singapore Expo, we do have workers who got infected," he said.
"But very quickly we went on a tighter regime, took the necessary precautions and we saw the last of those infections. We have to do the same thing in Changi now."
Article From & Read More ( Routine testing, PPE for some Changi Airport staff to avoid Covid-19 transmission: Ong Ye Kung - The Straits Times )[unable to retrieve full-text content]
[unable to retrieve full-text content]
2020年10月20日、医学誌『blood』にて3レジメン以上の治療歴のある再発難治性多発性骨髄腫患者に対する抗CD38モノクローナル抗体薬であるサークリサ（一般名：イサツキシマブ、以下サークリサ）±デキサメタゾン療法の有効性、安全性を検証した第2相試験（NCT01084252）の結果がNational and Kapodistrian University of AthensのMeletios A Dimopoulos氏らにより公表された。
本試験は、プロテアソーム阻害薬（PI）、免疫調整薬（IMiD）を含む3レジメン以上の治療歴のある再発難治性多発性骨髄腫患者（N＝164人）に対して28日を1サイクルとして最初のサイクルは1週間間隔で4回（1、8、15、22日目）、2サイクル以降は2週間間隔で2回（1、15日目）サークリサ20mg/kg単剤療法を投与する群、または28日を1サイクルとして最初のサイクルは1週間間隔で4回（1、8、15、22日目）、2サイクル以降は2週間間隔で2回（1、15日目）サークリサ20mg/kg＋1日1回デキサメタゾン40mg（75歳以上の患者には20mg）併用療法を投与する群に振り分け、主要評価項目として全奏効率（ORR）、副次評価項目として無増悪生存期間（PFS）、全生存期間（OS）、有害事象（AE）発症率などを検証した非盲検下の第2相試験である。
本試験に参加した患者の前レジメン中央値は4レジメンであった。主要評価項目である全奏効率（ORR）はサークリサ単剤群23.9％に対してサークリサ＋デキサメタゾン併用群43.6％、サークリサ単剤群に比べてサークリサ＋デキサメタゾン併用群で全奏効率（ORR）は高率であった（ORR：0.405、95％信頼区間：0.192-0.859、P=0.008）。
副次評価項目である無増悪生存期間（PFS）中央値はサークリサ単剤群4.9ヵ月に対してサークリサ＋デキサメタゾン併用群10.2ヵ月を示した。全生存期間（OS）中央値はサークリサ単剤群18.9ヵ月に対してサークリサ＋デキサメタゾン併用群17.3ヵ月を示した。
一方の安全性として、最も多くの患者で確認された有害事象（AE）はインフュージョンリアクション、血液関連毒性であった。なお、グレード3以上の感染症発症率はサークリサ単剤群22.0％に対してサークリサ＋デキサメタゾン併用群21.8％をであった。
以上の第2相試験の結果よりMeletios A Dimopoulos氏らは「3レジメン以上の治療歴のある再発難治性多発性骨髄腫患者に対する抗CD38モノクローナル抗体薬サークリサ＋デキサメタゾン併用療法は、サークリサ単剤療法に比べて全奏効率（ORR）をはじめ抗腫瘍効果を改善し、デキサメタゾン上乗せによる有害事象（AE）増加などの悪影響は確認されませんでした」と結論を述べている。
この記事に利益相反はありません。
▲ 김기남 삼성전자 DS부문 대표이사 부회장.
